Anti-Claudin-18.2 [CLDN18.2 v. 19 ]

Description:

Recombinant monoclonal antibody to Claudin-18.2. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the synthetic antibody CLDN18.2 v. 19 .

Clone Name:

CLDN18.2 v. 19

Published Application(s):

FC;

Published Species Reactivity:

Human

5

Products based on this clone:

{{heading}}

Please Select

Ab03747-10.3 Anti-Claudin-18.2 [CLDN18.2 v. 19 ]
Human
Human IgG1
Fc Silent™
Purified
Ships in 5-6 weeks

Ab03747-10.0 Anti-Claudin-18.2 [CLDN18.2 v. 19 ]
Human
Human IgG1
Purified
Ships in 5-6 weeks

Ab03747-3.0 Anti-Claudin-18.2 [CLDN18.2 v. 19 ]
Human
Mouse IgG2b
Purified
Ships in 5-6 weeks

Ab03747-3.3 Anti-Claudin-18.2 [CLDN18.2 v. 19 ]
Human
Mouse IgG2b
Fc Silent™
Purified
Ships in 5-6 weeks

Ab03747-23.0 Anti-Claudin-18.2 [CLDN18.2 v. 19 ]
Human
Rabbit IgG
Purified
Ships in 5-6 weeks

Loading...

UniProt Accession Number of Target Protein: P56856

Alternative Name(s) of Target: CLDN18.2; 2C6.9-HZ21; HuCLDN18.2-v. 19
Immunogen: The original antibody was generated by grafting CDRs of the parental mouse antibody onto human framework regions.

Specificity: This antibody is specific for human claudin-18.2 with no cross reactivity with claudin 18.1. Alterations in claudin expression can impair tight junction function, influence signaling pathways, and act as a tumor-promoting event in some epithelial cancers. Claudin 18.2 is overexpressed in various tumor type and is found to be a potentially important target in advanced gastric cancer.

Application Notes: The binding specificity of this antibody to human Claudin 18.2 expressed on the surface of HEK293 cells and Kato III cells was done using flow cytometry. The in-vivo anti-tumor activity of this antibody was evaluated in a syngeneic Mc38-huCLDN18.2 xenograft model in mice, which is a murine claudin18.2-/-mouse colon cancer cell line that has been engineered to expresses human claudin 18.2 (WO2021047599).

Antibody first published in: PMID: